Benign neonatal seizures

Benign Neonatal Seizures (BNS), also known as Benign Familial Neonatal Seizures (BFNS) when there is a family history, are a type of seizures occurring in newborn infants. These seizures are considered benign because they have a limited duration, typically occurring between the second and eighth day of life, and infants usually outgrow them without developing long-term neurological deficits or epilepsy.

Etiology and Pathophysiology[edit]

The exact cause of BNS is not fully understood, but it is believed to involve genetic factors. Mutations in the genes KCNQ2 and KCNQ3, which encode for potassium channel subunits, have been identified in many cases of BFNS. These channels are crucial for the regulation of neuronal excitability, and mutations can lead to increased neuronal firing, resulting in seizures.

Clinical Presentation[edit]

Infants with BNS experience seizures that are often characterized by apnea (pauses in breathing), tonic (stiffening) or clonic (jerking) movements of the limbs, and ocular movements such as blinking or staring. These seizures are generally brief but can occur multiple times a day while the condition persists.

Diagnosis[edit]

Diagnosis of BNS is based on the clinical presentation and the exclusion of other causes of neonatal seizures. Electroencephalogram (EEG) findings during this period may show characteristic patterns that support the diagnosis. Genetic testing can identify mutations in KCNQ2 or KCNQ3, confirming a diagnosis of BFNS.

Treatment[edit]

Treatment of BNS may not always be necessary, as the condition typically resolves on its own within weeks to months. However, in cases where seizures are frequent or severe, antiepileptic drugs (AEDs) may be used temporarily to control seizures. It is important to monitor infants for potential side effects of these medications.

Prognosis[edit]

The prognosis for infants with BNS is generally excellent. Most infants outgrow the seizures without any developmental delays or neurological issues. However, a small percentage may develop epilepsy later in life, necessitating ongoing monitoring.